Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
M.D. Anderson Cancer Center
Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Description
Primary Objectives • To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function. Secondary Objectives * To compare target radiation doses based on varying SPECT scan duration. Plot the variability in target radiation dose versus scan duration. * To compare the image quality and dosimetry results when considering the low, high, and both energy peaks of Lu-177. * To compare target radiation doses based on multiple imaging time points versus a single time point and identify which time point is most suited for…
Eligibility
- Age range
- Not specified
- Sex
- Male
- Healthy volunteers
- No
Eligibility Criteria * Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L. * Participants who agree to be imaged multiple times as defined in the study protocol. Exclusion Criteria * Pluvicto therapy patients without renal or marrow function complications * Participants who do not wish to be imaged multiple times as p…
Interventions
- DrugLu-177
Given by IV
- OtherSPECT
SPECT/CT
Location
- MD Anderson Cancer CenterHouston, Texas